Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Gene therapy biotech Genenta raises €13.2m in funding round
  2. Draper Q&A: upgrading CAR-T therapy manufacturing
  3. AZ licenses PARPi to Theragnostics to develop novel radiopharmaceuticals
  4. Can Pharmaoffer become the Amazon of pharma raw materials?
  5. Medidata CEO Tarek Sherif on the past and future of pharma R&D

Latest Content

The Antibody Dependent Cell Mediated Cytotoxicity

The medical indications of therapeutic antibodies (tAb) have been growing. The antibody dependent cell-mediated cytotoxicity (ADCC) is a mechanism of immune defence attributed to the mode of action of several tAb, in particular, tumour cell targeting.

Draper Q&A: upgrading CAR-T therapy manufacturing

Draper is seeking to update the manufacturing processes and technology used for CAR-T cancer therapies to improve the efficiency and access. The company’s head of precision medicine and cell bioprocessing Jenna Balestrini explains the issues with the current viral vector approach and how Draper’s four modules, and particularly the microfluidics electroporation system, can transform the CAR-T cell therapy space.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top